Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study

https://doi.org/10.1016/j.pnpbp.2008.01.016Get rights and content

Abstract

Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD). No information is available as to the influence of memantine on in vivo brain glutamate levels.

Hippocampal Glu levels were measured in cognitively impaired and normal individuals (n = 10) before and after 6 months of memantine treatment, using three dimensional high spatial resolution (0.5 cm3 voxels) proton magnetic resonance spectroscopy at 3 T. These measurements were also repeated in a non-treated cognitively normal group (n = 6).

Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region.

Memantine reduced hippocampal glutamate levels, which may be consistent with its anti-excitotoxic property.

Introduction

Glutamate (Glu) excitotoxicity through N-methyl-d-aspartic acid receptor (NMDAr) is a feature of Alzheimer's disease (AD) (Lipton, 2004). Glutamate is the main excitatory neurotransmitter in hippocampal circuits (Ottersen, 1991) and the hippocampus, crucial for memory performance, is an early affected target in the course of AD. Memantine, an NMDAr antagonist, is an approved treatment of moderate to severe AD. The mechanism of memantine is based on the modulation of NMDAr stimulation by glutamate. Recent reports suggest that it is also effective in mild to moderate stages (Bakchine and Loft, 2007).

Proton magnetic resonance spectroscopy (1H-MRS) enables a non-invasive sampling of biochemical composition of the brain. Studies of hippocampal region show a reduction in N-acetylaspartate (NAA) levels (Schuff et al., 1997, Block et al., 2002) in AD patients as compared with normal controls. Some authors suggested that the decrease in NAA was a disease, but not age-related phenomenon, as they observed that NAA levels declined significantly with age in the frontal cortex, but not in the hippocampus (Chen et al., 2000). Also reduction in cortical glutamate was reported in a few single voxel 1H-MRS AD studies (Antuono et al., 2001, Hattori et al., 2002), but the effects of memantine on in vivo hippocampal glutamate levels have not been examined.

Section snippets

Subjects

The subjects were recruited at the Center for Brain Health of the New York University (NYU) School of Medicine. They gave their written informed consent to NYU IRB (Institutional Review Board) approved protocols and received clinical assessments (general medical, neurological, psychiatric, and laboratory examinations) and an MRI (to exclude possible confounding comorbidities affecting cognition). The assessment included a Mini Mental State Examination (MMSE) (Folstein, 1983) and a Global

1H-MRS

Sample spectra from a paraxial slice containing the bilateral hippocampi of a 72 year old healthy female elderly control are shown in Fig. 3, superimposed on the MRI from the corresponding slice for anatomical reference. Metabolic maps from this slice are also presented to demonstrate the quality of localization, as reflected by the metabolic voids in the cerebrospinal fluid (CSF) spaces.

The SNRs for the metabolites, defined as their peak-height divided by twice the root-mean-square of the

Discussion

This clinical data shows that treatment with an uncompetitive NMDAr antagonist (memantine) decreases the Glu/Cr in the hippocampus. Others have observed an increase in cingulate glutamatergic turnover (Rowland et al., 2005) and an increase in frontal and cingulate blood flow, a surrogate for glutamate release (Holcomb et al., 2005), after acute ketamine administration. Moreover, in animal hippocampal homogenates ketamine stimulated the phosphate-activated glutaminase (PAG) activity (an enzyme

Conclusion

Overall, the results suggest that memantine decreases hippocampal Glu/Cr, possibly consistent with this drug's anti-excitotoxic properties. As decline in neuronal function cannot be entirely rejected, these data require replication with larger samples sizes.

Acknowledgements

We thank Drs. Andrew A. Maudsley of the University of Miami and Brian J. Soher of Duke University for the use of the SITools-FITT spectral modeling software, Ms. Rachel Mistur and Schantel Williams for cognitive testing and Ms. Nissa Perry for coordination of the MR evaluations. This study was supported by Forest Laboratories, Inc., NIH grants: AG12101, AG 22374, AG0305, P30 AG08051, EB01015 and NS050520, and a grant from the Mentored Medical Student Clinical Research (MMSCR) Program NCRR

References (42)

  • WaxmanE.A. et al.

    N-methyl-d-aspartate receptor-dependent regulation of the glutamate transporter excitatory amino acid carrier 1

    J Biol Chem

    (2007)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (1994)
  • AntuonoP.G. et al.

    Decreased glutamate 1 glutamine in Alzheimer's disease detected in vivo with 1H-MRS at 0.5 T

    Neurol

    (2001)
  • BakchineS. et al.

    Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study

    J Alzheimer's Dis

    (2007)
  • BernsteinM.A. et al.

    Effect of windowing and zero-filled reconstruction of MRI data on spatial resolution and acquisition strategy

    J Magn Reson Imaging

    (2001)
  • BlockW. et al.

    Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease

    Arch Neurol

    (2002)
  • BottomleyP.A.

    Spatial localization in NMR spectroscopy in vivo

    Ann NY Acad Sci

    (1987)
  • BrookerH.R. et al.

    Selective Fourier transform localization

    Magn Res Med

    (1987)
  • ChenJ.G. et al.

    Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate

    Acta Neurol Scand, Suppl

    (2000)
  • DanyszW. et al.

    Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications

    Pharmacol Rev

    (1998)
  • DawsonR.J. et al.

    Regulation of phosphate-activated glutaminase (PAG) by glutamate analogues

    Neurochem Res

    (1993)
  • Cited by (22)

    • Magnetic resonance spectroscopy analysis of neurochemical changes in the atrophic hippocampus of APP/PS1 transgenic mice

      2017, Behavioural Brain Research
      Citation Excerpt :

      The atrophy of the hippocampus could be connected with the reduction of NAA and Glu and might mainly be due to the apoptosis of glutamate neurons. A number of studies in AD patients have found decreased Glu levels [14,39], and several studies have reported the utility of memantine in treating AD patients accompanied by a significant increase in Glu levels [39]. In addition, the decrease in NAA and increase in mIn levels might provide insight into the treatment of AD.

    • Imaging Approaches to Cerebral Cortex Pathology

      2017, The Cerebral Cortex in Neurodegenerative and Neuropsychiatric Disorders: Experimental Approaches to Clinical Issues
    • Brain energy metabolism in glutamate-receptor activation and excitotoxicity: Role for APC/C-Cdh1 in the balance glycolysis/pentose phosphate pathway

      2013, Neurochemistry International
      Citation Excerpt :

      However, open-ion channel antagonists with rapid turnover, such as memantine, have been suggested to be a better therapeutic strategy for the treatment of Alzheimer’s disease because they block the opened channels at a fast off-rate, impeding its accumulation and hence interference with normal glutamatergic transmission (Lipton, 2004). Moreover, it has also been demonstrated that memantine decreases glutamate levels in the hippocampus of Alzheimer’s disease patients, which is consistent with its protection against excitotoxicity (Glodzik et al., 2008). Thus, excitotoxicity can be considered a potential therapeutic target against neurological disorders; therefore, it is worth better understanding the molecular players of this type of neuronal death.

    • Biomarkers for Alzheimer's disease therapeutic trials

      2011, Progress in Neurobiology
      Citation Excerpt :

      In addition, functional imaging using PET, single photon emission computed tomography (SPECT) or fMRI allow the effects of therapy on brain function to be assessed through measurement and mapping of cerebral glucose utilization (FDG-PET), perfusion (SPECT, fMRI) or activation (fMRI) and has been proposed as outcome measures in AD trials (Alexander et al., 2002). A number of imaging modalities offer other non-invasive ways to assess brain changes associated with AD: micro-structural changes may be detected with magnetization transfer or diffusion imaging and cerebral metabolite levels may be measured with MR spectroscopy (MRS) (Kantarci et al., 2007; Krishnan et al., 2003; Glodzik et al., 2008). Functional imaging can be used in a diagnostic capacity in clinical trials for enrichment of study populations.

    • Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease

      2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    View all citing articles on Scopus
    View full text